Efficacy of Two Doses of Duloxetine and Amitriptyline in Subjects With Refractory Chronic Cough (MACS-1)
A Randomized, Double-blind, Placebo-controlled, Dose-escalation Study Evaluating the Efficacy of Two Doses of Duloxetine & Amitriptyline in Subjects With Refractory Chronic Cough
Sponsor: Mayo Clinic
A PHASE2 clinical study on Refractory Chronic Cough, this trial is actively recruiting participants. The trial is conducted by Mayo Clinic and has accumulated 8 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Feb 2026 — Present [monthly]
Recruiting PHASE2
-
May 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2024 — May 2025 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Mar 2023 — May 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Mar 2023 [monthly]
Recruiting PHASE2
-
Dec 2021 — Dec 2022 [monthly]
Recruiting PHASE2
First recorded
Nov 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Mayo Clinic
For direct contact, visit the study record on ClinicalTrials.gov .